Magic mushroom compound tested for cancer pain that opioids Can't touch

NCT ID NCT06001749

First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 26 times

Summary

This study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approach is safe, acceptable, and worth studying further.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

psilocybin (a psychedelic compound)

What this could lead to

If it works, this could offer a new way to manage severe pain in advanced cancer patients who don't respond to opioids.

What could go wrong

This is a very small early-phase trial with only 15 people, so results may not apply broadly. Psilocybin can cause intense psychological effects and is not yet proven for pain relief.

Conditions

The condition(s) this trial relates to.

agnosia cancer opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.